Background & Objective: Recently, high-dose docetaxel has been proved to be an effective antineoplastic drug in the treatment of metastatic breast cancer.However,there was a few reports about moderate-dose docetaxel and Adriamycin in the treatment of metastatic breast cancer. This study was designed to observe the response rate and toxic reaction of Taxotere and Taxotere plus Adriamycin in the treatment of metastatic breast cancer.
Methods: From September 1996 to April 2000, 34 cases with metastatic breast cancer, which were treated in Department of Oncology, The Second Central Hospital in Tianjin, were included in the study. For group A (14 cases), Taxotere single agent was administered at a dose of 75 mg/m(2) iv 1 hour. For group B, Taxotere was administered at a dose of 60 mg/m(2) combined with Adriamycin 50 mg/m(2) i.v. 1 hour. The same schedule for both groups was repeated every 21 days, with three cycles for all patients.
Results: The recent response rates of group A and group B were 57.14% (8/14) and 75.0% (15/20), respectively. The 2-and 4-year survival rates were 35.7%, 14.3% for group A, and 40.0%, 15.0% for group B. The median overall survival durations of group A and group B were 22 months and 23 months. The median overall response durations of these two groups were 10 and 11 months, respectively. The main adverse reactions of these two groups were neutropenia, nausea, vomiting, stomatitis, diarrhea, alopecia, fatigue, myalgia, fluid retention, and skin flushing. Grade 3 and grade 4 neutropenia occurred in group A and group B were 57.1% (8/14) and 70.0% (14/20), respectively.
Conclusion: Taxotere is effective in the treatment of metastatic breast cancer. The toxic reactions are tolerable.
Download full-text PDF |
Source |
---|
Breast Cancer Res Treat
January 2025
Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.
Purpose: Interstitial lung disease (ILD) is a well described and potentially fatal complication of trastuzumab-deruxtecan (T-DXd). It is currently unknown if specific monitoring is beneficial in the early detection of ILD in these patients. We describe the efficacy and feasibility of a novel ILD monitoring protocol in breast cancer patients treated with T-DXd at our institution.
View Article and Find Full Text PDFJ Mater Chem B
January 2025
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, 226025, India.
This research demonstrates the design and development of a novel dual-targeting, pH-sensitive liposomal (pSL) formulation of 5-Fluorouracil (5-FU), , (5-FU-iRGD-FA-pSL) to manage breast cancer (BC). The motivation to explore this formulation is to overcome the challenges of systemic toxicity and non-specific targeting of 5-FU, a conventional chemotherapeutic agent. The proposed formulation also combines folic acid (FA) and iRGD peptides as targeting ligands to enhance tumor cell specificity and penetration, while the pH-sensitive liposomes ensure the controlled drug release in the acidic tumor microenvironment.
View Article and Find Full Text PDFObjective: Sodium-glucose cotransporter (SGLT) 2 inhibitors are expected to demonstrate secondary effects against malignancy. However, long-term and large-scale data are required to evaluate the effects of SGLT2 inhibitors on malignancy, which has not been sufficiently studied in clinical practice. This study aimed to evaluate the association between SGLT2 inhibitors and malignancy using the spontaneous adverse reaction database.
View Article and Find Full Text PDFRadiol Case Rep
March 2025
Maimonides Medical Center, Department of Radiology 4802 10th Avenue, Brooklyn, NY 11219, USA.
Leptomeningeal carcinomatosis is a form of advanced metastatic disease conferring poor prognosis, most commonly associated with melanoma, small cell lung cancer, and breast cancer. In rare cases it has been shown to be associated with stroke thought to be related to vasculopathy caused by tumoral infiltration of cerebral vasculature. We present a case of acute cerebellar infarction in a patient with metastatic breast cancer complicated by leptomeningeal carcinomatosis, admitted for worsening metastatic disease.
View Article and Find Full Text PDFDifferences/disorders of sex development (DSDs) are a diverse group of congenital conditions that result in disagreement between an individual's sex chromosomes, gonads, and/or anatomical sex. The 46, XY DSD group is vast and includes various conditions caused by genetic variants, hormonal imbalances, or abnormal sensitivity to testicular hormones, leading to varying degrees of under-virilization. A 19-year-old phenotypically normal female from Kakamega, Kenya, presented with primary amenorrhea.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!